https://www.selleckchem.com/
6%), treatment with sorafenib and surgery/trans-arterial chemoembolization (TACE). Patients who underwent any treatment presented "early recurrences" less frequently, and more extrahepatic metastasis. This unbalanced distribution was included in the propensity score matching, with correct calibration and discrimination (receiving operator curve of 0.81 [CI 0.72;0.88]). After matching, the adjusted effect on PRS for any treatment was HR of 0.2 (0.10;0.33); P.0001, for sorafenib therapy HR of 0.4 (0.27;0.77); P=.003, and for surgery/TACE HR of 0.4 (0.18;0
Like
Comment
Share
